等待开盘 10-16 09:30:00 美东时间
+0.050
+2.75%
Rademikibart, an investigational anti-IL-4Rα antibody, showed rapid and significant improvements in lung function and asthma control, particularly in patients with elevated type 2 inflammatory markers. It reduced annualized asthma exacerbations by 63%-69% in subgroups with high biomarkers. The Phase 2b trial results support ongoing Seabreeze STAT studies for asthma and COPD, with topline data expected in H1 2026.
09-29 13:00
Connect Biopharma Holdings ( ($CNTB) ) has issued an announcement. Between Sept...
09-16 21:26
Gamehaus Holdings涨66.7%;房多多涨64.8%;Mercurity Fintech涨41.5%
08-30 17:08
炒股就看金麒麟分析师研报,权威,专业,及时,全面,助您挖掘潜力主题机会! 近日,天辰生物医药(苏州)股份有限公司(以下简称“天辰生物”)递表港交所,拟...
08-29 17:11
炒股就看金麒麟分析师研报,权威,专业,及时,全面,助您挖掘潜力主题机会! 近日,湖南麦济生物技术股份有限公司(以下简称“麦济生物”)向港交所递交主板上...
08-29 17:08
Connect Biopharma collaborates with the Jovante Woods Foundation to expand asthma education across the U.S., raising awareness about acute asthma attacks. The partnership marks 15 years since Jovante Woods' death from an asthma attack. The Foundation, established by Ickey and Chandra Woods, focuses on prevention and treatment education. Connect, developing a novel asthma treatment, supports the initiative with a video story and community events d...
08-14 12:00
今日重点评级关注:HC Wainwright & Co.:维持Insmed"买入"评级,目标价从120美元升至240美元;巴克莱:维持Transocean"超配"评级,目标价从3.5美元升至4美元
08-14 09:25
Connect Biopharma press release (NASDAQ:CNTB): Q2 GAAP EPS of -$0.23. More on Connect Biopharma Seeking Alpha’s Quant Rating on Connect Biopharma Historical earnings data for Connect Biopharma Financi...
08-14 00:38
Connect Biopharma Hldgs (NASDAQ:CNTB) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.22) by 4.55 percent. This is a 185.19 percent decrease over earnings of $0.27 per
08-13 21:14
Connect Biopharma reported significant progress in Q2 2025, advancing its Phase 2 Seabreeze STAT studies for asthma and COPD, showcasing positive data supporting rademikibart’s potential. The company also submitted a new drug application in China via licensee Simcere and terminated its ADR program, listing directly on Nasdaq to enhance institutional visibility. Additionally, Jim Schoeneck, an industry veteran, was appointed to the Board, bringing...
08-13 13:00